Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01481701
What this trial is testing

A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Who this might be right for
Ovarian CarcinomaRelapse
Jules Bordet Institute 90
Early research (Phase 1)Ended earlyNCT01016054
What this trial is testing

The Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Who this might be right for
CarcinomaOvarian CancerOvarian Diseases+1 more
Astellas Pharma Inc 4
Not applicableStudy completedNCT00368420
What this trial is testing

Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
AGO Study Group 122
Not applicableEnded earlyNCT07000344
What this trial is testing

Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

Who this might be right for
Ovarian Cancer
Peking Union Medical College Hospital 5
Testing effectiveness (Phase 2)UnknownNCT06161272
What this trial is testing

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
Guangxi Medical University 80
Early research (Phase 1)Study completedNCT01281514
What this trial is testing

Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)WithdrawnNCT00369954
What this trial is testing

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Early research (Phase 1)Study completedNCT03695380
What this trial is testing

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Who this might be right for
OVARIAN CANCER
Hoffmann-La Roche 77
Early research (Phase 1)WithdrawnNCT02050009
What this trial is testing

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Papillary Serous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube Cancer+3 more
Fox Chase Cancer Center
Not applicableStudy completedNCT02222883
What this trial is testing

Prevalence of BRCA in Patients With Ovarian Cancer

Who this might be right for
BRCA StatusOvarian Cancer
AGO Research GmbH 530
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT00230542
What this trial is testing

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute 44
Testing effectiveness (Phase 2)UnknownNCT05158062
What this trial is testing

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian Epithelial
Kosei Hasegawa, MD, PhD 35
Large-scale testing (Phase 3)Study completedNCT03402841
What this trial is testing

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Who this might be right for
Non-Germline BRCA Mutated Ovarian Cancer
AstraZeneca 279
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Early research (Phase 1)UnknownNCT01387399
What this trial is testing

Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
University Hospital, Bonn 9
Testing effectiveness (Phase 2)Ended earlyNCT04826198
What this trial is testing

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Who this might be right for
Ovarian Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Testing effectiveness (Phase 2)Study completedNCT01941316
What this trial is testing

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Who this might be right for
Small Cell Lung CarcinomaNon Small Cell Lung CarcinomaIrinotecan Sensitive Cancers
Cancer Research and Biostatistics Clinical Trials Consortium 78
Testing effectiveness (Phase 2)Ended earlyNCT00005029
What this trial is testing

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Next Page